TY - JOUR
T1 - Therapies for patients with coexisting heart failure with reduced ejection fraction and non-alcoholic fatty liver disease
AU - Arriola-Montenegro, Jose
AU - Beas, Renato
AU - Cerna-Viacava, Renato
AU - Chaponan-Lavalle, Andres
AU - Hernandez Randich, Karla
AU - Chambergo-Michilot, Diego
AU - Flores Sanga, Herson
AU - Mutirangura, Pornthira
N1 - Publisher Copyright:
© 2023 Baishideng Publishing Group Co. All rights reserved.
PY - 2023/7/26
Y1 - 2023/7/26
N2 - Heart failure with reduced ejection fraction (HFrEF) and nonalcoholic fatty liver disease (NAFLD) are two common comorbidities that share similar pathophysiological mechanisms. There is a growing interest in the potential of targeted therapies to improve outcomes in patients with coexisting HFrEF and NAFLD. This manuscript reviews current and potential therapies for patients with coexisting HFrEF and NAFLD. Pharmacological therapies, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoids receptor antagonist, and sodium-glucose cotransporter-2 inhibitors, have been shown to reduce fibrosis and fat deposits in the liver. However, there are currently no data showing the beneficial effects of sacubitril/valsartan, ivabradine, hydralazine, isosorbide nitrates, digoxin, or beta blockers on NAFLD in patients with HFrEF. This study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these comorbidities. Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.
AB - Heart failure with reduced ejection fraction (HFrEF) and nonalcoholic fatty liver disease (NAFLD) are two common comorbidities that share similar pathophysiological mechanisms. There is a growing interest in the potential of targeted therapies to improve outcomes in patients with coexisting HFrEF and NAFLD. This manuscript reviews current and potential therapies for patients with coexisting HFrEF and NAFLD. Pharmacological therapies, including angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, mineralocorticoids receptor antagonist, and sodium-glucose cotransporter-2 inhibitors, have been shown to reduce fibrosis and fat deposits in the liver. However, there are currently no data showing the beneficial effects of sacubitril/valsartan, ivabradine, hydralazine, isosorbide nitrates, digoxin, or beta blockers on NAFLD in patients with HFrEF. This study highlights the importance of considering HFrEF and NAFLD when developing treatment plans for patients with these comorbidities. Further research is needed in patients with coexisting HFrEF and NAFLD, with an emphasis on novel therapies and the importance of a multidisciplinary approach for managing these complex comorbidities.
KW - Cardiovascular disease
KW - Heart Failure
KW - Heart failure reduced ejection fraction
KW - Non-alcoholic fatty liver disease
KW - Novel therapies
UR - http://www.scopus.com/inward/record.url?scp=85168351909&partnerID=8YFLogxK
U2 - 10.4330/wjc.v15.i7.328
DO - 10.4330/wjc.v15.i7.328
M3 - Artículo de revisión
AN - SCOPUS:85168351909
SN - 1949-8462
VL - 15
SP - 328
EP - 341
JO - World Journal of Cardiology
JF - World Journal of Cardiology
IS - 7
ER -